Evidence map›Paper›PMID 24057400›Full record

ArticleNeurochemical research2013

Neurite outgrowth of PC12 cells by 4'-O-β-D-glucopyranosyl-3',4-dimethoxychalcone from Brassica rapa L. 'hidabeni' was enhanced by pretreatment with p38MAPK inhibitor.

Atsuyoshi Nishina, Hirokazu Kimura, Hiroyuki Tsukagoshi, Kunihisa Kozawa, Mamoru Koketsu, Masayuki Ninomiya, Daisuke Sato, Yutaro Obara, Shoei Furukawa

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. The Effect of Protein-Rich Extract fromMolecules (Basel, Switzerland) · 2020
    Article
  3. Article
  4. Differential gene expression profile analysis in corticosterone-treated PC12 cells.International journal of clinical and experimental pathology · 2018
    Article
  5. Modulation of neurotrophic signaling pathways by polyphenols.Drug design, development and therapy · 2016
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Atsuyoshi NishinaCollege of Science and Technology, Nihon University, 1-5-1, Kandasurugadai, Chiyoda, Tokyo, 101-0062, Japan, nishina.atsuyoshi@nihon-u.ac.jp.
Hirokazu Kimura
Hiroyuki Tsukagoshi
Kunihisa Kozawa
Mamoru Koketsu
Masayuki Ninomiya
Daisuke Sato
Yutaro Obara
Shoei Furukawa
Gunma Prefectural Institute of Public Health and Environmental Sciences · JPGifu University · JPYamagata University · JPGifu Pharmaceutical University · JPNihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cellular effects of eleven compounds including chalcone glycosides isolated from Brassica rapa L. 'hidabeni' and their synthetic derivatives were studied in rat pheochromocytoma PC12 cells. Of the compounds tested, 4'-O-β-D-glucopyranosyl-3',4-dimethoxychalcone (A2) significantly increased the levels of the phosphorylated forms of extracellular signal-regulated kinases 1/2 (ERK 1/2), p38 mitogen-activated protein kinase (p38MAPK), and stress-activated protein kinases/Jun amino-terminal kinases (JNK/SAPK), but it did not affect Akt. Nerve growth factor (NGF), a well-known neurotrophic factor, increased the levels of phosphorylated ERK1/2, JNK/SAPK, and Akt but not p38MAPK, which may mediate marked neurite outgrowth. Signals evoked by A2 shared common characteristics with those induced by NGF; therefore, we evaluated the neuritogenic activity of A2 and found it induced only weak neurite outgrowth. However, this effect was enhanced by pre-treatment with a p38MAPK inhibitor, suggesting that the phosphorylation of p38MAPK down-regulated neurite outgrowth. From the results of this study, it was found that A2 in combination with a p38MAPK inhibitor can induce NGF-like effects. Hence, a combination of chalcone glycosides containing A2 and a p38MAPK inhibitor increases the likelihood that chalcone glycosides could be put to practical use in the form of drugs or alternative medicines to maintain neural health.

Indexed as

AnimalsChalconesImidazolesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 3Neuritesp38 Mitogen-Activated Protein KinasesPC12 CellsPyridinesRats4'-O-beta-D-glucopyranosyl-3',4-dimethoxychalconeChalconesImidazolesMitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesPyridinesSB 203580

Identifiers

PMID24057400
OpenAlexW1981318938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.